Immutep On Sunday Announced Completion Of The Safety Lead-In And Opening Of The Randomized Phase II Of The AIPAC-003 Phase II/III Trial In Metastatic Breast Cancer
Portfolio Pulse from Charles Gross
Immutep Limited has announced the completion of the safety lead-in and the opening of the randomized Phase II of the AIPAC-003 Phase II/III trial in metastatic breast cancer. The trial is evaluating the combination of 90mg of eftilagimod alpha (efti) with paclitaxel, with no safety or tolerability issues reported.
November 06, 2023 | 9:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's successful completion of the safety lead-in and the opening of the randomized Phase II of the AIPAC-003 trial could potentially boost investor confidence.
The successful completion of the safety lead-in and the opening of the randomized Phase II of the AIPAC-003 trial indicates progress in Immutep's product development. This could potentially boost investor confidence and have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100